MetaCap

NovaBridge Biosciences (NBP) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Unicycive Therapeutics (UNCY) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 38.0% versus a loss of 80.4%. Over five years, UNCY leads with a -88.5% price change compared with -98.7% for NBP. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $96.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NBP-80.38%UNCY-37.96%
+66%-11%-88%
Nov 21, 20251 yearNov 20, 2026
NBP-98.79%UNCY-87.07%
+18%-43%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NBP versus UNCY key metrics
MetricNBPUNCY
Share price$0.83$3.35
Market cap$96.28M$97.77M
1-day change-5.66%-5.10%
YTD return-79.15%-41.94%
1-year return-80.38%-37.96%
5-year return-98.69%-88.53%
Forward P/E—4.86
EPS (TTM)$-0.69$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-46.27M$-26.55M
52-week high$5.19$8.74
52-week low$0.751$3.33
Distance from 52-week high-84.01%-61.67%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+944.58%+685.07%
Average volume515.66K963.80K
Shares outstanding116.00M29.18M
Employees3021
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UNCY has outperformed NBP by 42.4 percentage points over the past year.

About NovaBridge Biosciences

NBP stock →

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.

Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

NBP vs UNCY FAQ

Which is bigger, NovaBridge Biosciences or Unicycive Therapeutics?

Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $96.28M for NovaBridge Biosciences (NBP).

Which stock has performed better over the past year, NBP or UNCY?

UNCY returned -37.96% over the past 12 months, compared with -80.38% for NBP (price return, excluding dividends). Past performance does not predict future results.

Are NovaBridge Biosciences and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons